| Overview |
| bs-2984R-Cy7 |
| PLB(Ser16) Polyclonal Antibody, Cy7 Conjugated |
| IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human |
| Mouse, Rat, Dog, Cow, Pig, Rabbit |
| Specifications |
| Cy7 |
| Rabbit |
| KLH conjugated synthetic phosphopeptide derived from human Cardiac phospholamban around the phosphorylation site of Ser16 |
| Ser16 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 5350 |
| Cytoplasm, Cell membrane |
| Phospholamban phospho S16; p-Phospholamban phospho S16; p-PLBS16; Cardiac phospholamban; CMD1P; PLB; PLN; PPLA_HUMAN. |
| Defects in PLN are the cause of cardiomyopathy dilated type 1P (CMD1P) . Dilated cardiomyopathy is a disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death.Defects in PLN are the cause of cardiomyopathy familial hypertrophic type 18 (CMH18) . CMH18 is a hereditary heart disorder characterized by ventricular hypertrophy, which is usually asymmetric and often involves the interventricular septum. The symptoms include dyspnea, syncope, collapse, palpitations, and chest pain. They can be readily provoked by exercise. The disorder has inter- and intrafamilial variability ranging from benign to malignant forms with high risk of cardiac failure and sudden cardiac death. |
| Application Dilution |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz